Tolulope Afolaranmi, M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Nigeria | 18 | 2024 | 777 | 0.920 |
Why?
|
Neglected Diseases | 2 | 2023 | 67 | 0.910 |
Why?
|
Antisickling Agents | 2 | 2021 | 72 | 0.360 |
Why?
|
Mental Health | 2 | 2023 | 3271 | 0.340 |
Why?
|
Hydroxyurea | 2 | 2021 | 284 | 0.330 |
Why?
|
Elephantiasis, Filarial | 1 | 2023 | 31 | 0.220 |
Why?
|
Leprosy | 1 | 2023 | 126 | 0.220 |
Why?
|
Chlorhexidine | 2 | 2023 | 160 | 0.220 |
Why?
|
Anemia, Sickle Cell | 2 | 2021 | 1065 | 0.200 |
Why?
|
Internship and Residency | 1 | 2022 | 5952 | 0.190 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2020 | 96 | 0.170 |
Why?
|
Cross-Sectional Studies | 13 | 2024 | 26348 | 0.170 |
Why?
|
Anti-Infective Agents, Local | 1 | 2021 | 248 | 0.160 |
Why?
|
Infant, Newborn, Diseases | 1 | 2023 | 592 | 0.150 |
Why?
|
Dengue Virus | 1 | 2018 | 204 | 0.140 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2020 | 387 | 0.140 |
Why?
|
Dengue | 1 | 2018 | 258 | 0.120 |
Why?
|
Oropharyngeal Neoplasms | 1 | 2021 | 493 | 0.120 |
Why?
|
Papillomaviridae | 1 | 2021 | 1135 | 0.120 |
Why?
|
Child, Orphaned | 1 | 2015 | 55 | 0.120 |
Why?
|
Infectious Disease Transmission, Vertical | 1 | 2021 | 1359 | 0.120 |
Why?
|
Immunoglobulin M | 1 | 2018 | 1528 | 0.110 |
Why?
|
Income | 1 | 2022 | 1878 | 0.110 |
Why?
|
Public-Private Sector Partnerships | 1 | 2013 | 123 | 0.100 |
Why?
|
Feasibility Studies | 1 | 2023 | 5308 | 0.100 |
Why?
|
Mothers | 1 | 2023 | 2210 | 0.100 |
Why?
|
HIV Infections | 4 | 2024 | 17492 | 0.100 |
Why?
|
Case Management | 1 | 2013 | 276 | 0.100 |
Why?
|
Adaptation, Psychological | 1 | 2022 | 2664 | 0.100 |
Why?
|
Fever | 1 | 2018 | 1622 | 0.090 |
Why?
|
Umbilical Cord | 2 | 2023 | 179 | 0.090 |
Why?
|
Pilot Projects | 1 | 2023 | 8730 | 0.090 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2021 | 2181 | 0.080 |
Why?
|
Vulnerable Populations | 1 | 2015 | 717 | 0.080 |
Why?
|
Papillomavirus Infections | 1 | 2021 | 1637 | 0.080 |
Why?
|
Health Knowledge, Attitudes, Practice | 2 | 2021 | 4049 | 0.080 |
Why?
|
Malaria | 2 | 2018 | 1240 | 0.070 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2020 | 2040 | 0.070 |
Why?
|
Communicable Disease Control | 1 | 2013 | 857 | 0.070 |
Why?
|
Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 3246 | 0.070 |
Why?
|
Antimalarials | 1 | 2013 | 910 | 0.070 |
Why?
|
Urban Population | 1 | 2015 | 2047 | 0.070 |
Why?
|
Prevalence | 5 | 2024 | 15879 | 0.060 |
Why?
|
Adult | 12 | 2024 | 223528 | 0.060 |
Why?
|
Young Adult | 9 | 2024 | 60038 | 0.060 |
Why?
|
Rural Population | 1 | 2015 | 2317 | 0.060 |
Why?
|
Humans | 19 | 2024 | 768369 | 0.050 |
Why?
|
Hypertension | 1 | 2023 | 8610 | 0.050 |
Why?
|
HIV-1 | 1 | 2020 | 6909 | 0.050 |
Why?
|
Asthma | 1 | 2022 | 6274 | 0.050 |
Why?
|
Primary Health Care | 2 | 2022 | 4736 | 0.050 |
Why?
|
Poverty Areas | 1 | 2023 | 265 | 0.050 |
Why?
|
Ameloblastoma | 1 | 2021 | 42 | 0.040 |
Why?
|
Tuberculosis | 1 | 2013 | 2029 | 0.040 |
Why?
|
Health Personnel | 1 | 2013 | 3384 | 0.040 |
Why?
|
Female | 13 | 2024 | 396926 | 0.040 |
Why?
|
Hematocrit | 1 | 2020 | 625 | 0.040 |
Why?
|
Socioeconomic Factors | 3 | 2020 | 7863 | 0.040 |
Why?
|
Focus Groups | 1 | 2024 | 1448 | 0.040 |
Why?
|
Food | 1 | 2022 | 770 | 0.040 |
Why?
|
Cardiovascular Diseases | 1 | 2023 | 15638 | 0.040 |
Why?
|
Vaginal Smears | 1 | 2020 | 501 | 0.040 |
Why?
|
Seroepidemiologic Studies | 1 | 2018 | 406 | 0.040 |
Why?
|
Middle Aged | 8 | 2024 | 223406 | 0.030 |
Why?
|
Infant Mortality | 1 | 2021 | 756 | 0.030 |
Why?
|
Male | 10 | 2024 | 364761 | 0.030 |
Why?
|
Adolescent | 5 | 2024 | 89163 | 0.030 |
Why?
|
Anti-Retroviral Agents | 1 | 2024 | 1792 | 0.030 |
Why?
|
Cholesterol | 1 | 2023 | 2910 | 0.030 |
Why?
|
DNA, Viral | 1 | 2021 | 2203 | 0.030 |
Why?
|
Health Care Surveys | 1 | 2021 | 2437 | 0.030 |
Why?
|
United States | 1 | 2022 | 73120 | 0.030 |
Why?
|
Infant | 3 | 2023 | 36496 | 0.030 |
Why?
|
Directly Observed Therapy | 1 | 2013 | 139 | 0.030 |
Why?
|
Infant, Newborn | 2 | 2023 | 26394 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2021 | 2200 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 3813 | 0.020 |
Why?
|
Diagnostic Errors | 1 | 2018 | 1282 | 0.020 |
Why?
|
Risk Factors | 3 | 2024 | 74915 | 0.020 |
Why?
|
Pregnancy | 2 | 2024 | 30179 | 0.020 |
Why?
|
Child Welfare | 1 | 2015 | 523 | 0.020 |
Why?
|
Housing | 1 | 2015 | 679 | 0.020 |
Why?
|
Family Characteristics | 1 | 2015 | 1001 | 0.020 |
Why?
|
Food Supply | 1 | 2015 | 543 | 0.020 |
Why?
|
Anti-HIV Agents | 1 | 2024 | 4563 | 0.020 |
Why?
|
Child | 3 | 2024 | 80856 | 0.020 |
Why?
|
Head and Neck Neoplasms | 1 | 2021 | 2915 | 0.020 |
Why?
|
Genotype | 1 | 2021 | 13045 | 0.020 |
Why?
|
Diet | 1 | 2024 | 8098 | 0.020 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2021 | 4083 | 0.020 |
Why?
|
Program Evaluation | 1 | 2013 | 2508 | 0.020 |
Why?
|
Antitubercular Agents | 1 | 2013 | 1390 | 0.020 |
Why?
|
Child, Preschool | 2 | 2020 | 42620 | 0.010 |
Why?
|
Health Surveys | 1 | 2015 | 4056 | 0.010 |
Why?
|
Quality of Life | 1 | 2023 | 13497 | 0.010 |
Why?
|
Health Status | 1 | 2015 | 4096 | 0.010 |
Why?
|
Referral and Consultation | 1 | 2013 | 3629 | 0.010 |
Why?
|
Treatment Outcome | 2 | 2020 | 65408 | 0.010 |
Why?
|
Aged | 2 | 2021 | 171514 | 0.010 |
Why?
|
Stroke | 1 | 2020 | 9790 | 0.010 |
Why?
|